Kestra Medical Technologies Ltd. ( (KMTS) ) has released its Q3 earnings. Here is a breakdown of the information Kestra Medical Technologies Ltd. presented to its investors.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kestra Medical Technologies, Ltd. is a commercial-stage company specializing in wearable medical devices and digital healthcare solutions aimed at improving cardiovascular disease outcomes through innovative monitoring and therapeutic technologies.
In its third quarter fiscal 2025 earnings report, Kestra Medical Technologies announced significant revenue growth and strategic advancements, following its recent initial public offering. The company reported a substantial increase in revenue and gross margin compared to the previous year, reflecting its expanding market presence.
Key financial highlights include a revenue of $15.1 million, marking an 82% increase from the prior year, and a gross margin improvement to 43.4% from 10.6%. The company also completed its IPO, raising approximately $205.2 million, and expanded its insurance coverage, now reaching over 285 million health plan members in the U.S. Despite these gains, Kestra reported a GAAP net loss of $21.8 million, similar to the previous year, with adjusted EBITDA loss slightly increasing to $16.3 million.
Looking forward, Kestra’s management remains optimistic, projecting a revenue growth of approximately 109% to 110% for the fiscal year ending April 30, 2025. The company aims to continue its growth trajectory by focusing on expanding its commercial operations and enhancing its revenue cycle management capabilities.